CMPX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
27.0M
+32.9%
20.3M
+12.8%
18.0M
+13.7%
15.8M
-24.9%
21.1M
R&D
19.6M
+46.2%
13.4M
-2.1%
13.7M
+6.6%
12.8M
-21.9%
16.4M
SG&A
7.4M
+7.2%
6.9M
+60.0%
4.3M
+44.4%
3.0M
-35.7%
4.7M
Operating Income
-26979000
-32.9%
-20299000
-12.8%
-17990000
-13.7%
-15817000
+24.9%
-21066000
EBITDA
-26958000
-32.9%
-20284000
-12.9%
-17973000
-13.8%
-15798000
+24.6%
-20966000
Net Income
-25154000
-37.3%
-18317000
-16.6%
-15716000
-10.2%
-14259000
+28.3%
-19881000
EPS (Basic)
$-0.13
-30.0%
$-0.10
-25.0%
$-0.08
+0.0%
$-0.08
+42.9%
$-0.14
EPS (Diluted)
$-0.13
-30.0%
$-0.10
-25.0%
$-0.08
+0.0%
$-0.08
+42.9%
$-0.14
Shares (Diluted)
186.8M
+0.2%
186.4M
+0.5%
185.5M
+9.9%
168.8M
+22.1%
138.3M
Compass Therapeutics (CMPX) โ€” Financials